RAIsonance, Inc. Announces BARDA Contract to Continue Development of the AudibleHealth Dx Diagnostic SaMD for COVID-19 and Influenza Through AI-Powered Cough Analysis

RAIsonance, the leader in artificial intelligence-powered analysis of FCV, announced  it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), a component of the Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), a U.S. government agency.

Latest Insights: Why Only AI and Data Analytics Can Stop Financial Criminals

The contract consists of just over $749,000 allocated to the continued development of RAIsonance’s AudibleHealth Dx Software as a Medical Device (SaMD). The device is designed to analyze a user’s Forced Cough Vocalization (FCV) in the diagnosis of illness, with the current focus on both COVID-19 and Influenza. The cloud-based artificial intelligence processing platform uses a mobile app interface for cough collection and is designed to deliver test results in about 2 minutes within the app. The primary objectives of the contract are to complete the execution of the clinical validation studies for COVID-19 and Influenza and to complete a de novo submission to the U.S. Food and Drug Administration before the end of 2023.

“We are elated to have BARDA’s support. Their strategic guidance and extensive expertise will speed our efforts to deliver the best possible diagnostic SaMD to market and help ensure that we fulfill our mission to meaningfully impact global health with such an innovative diagnostic solution,” said Kitty Kolding, Co-Founder and CEO at RAIsonance.

Hot AI News: Stagwell’s First Free Generative AI Writing Tool, Taylor to Debut at SXSW 2023

RAIsonance’s SaMD is designed to use only software to diagnose disease, without any wet or biological samples of any kind. The non-invasive test requires just 10 intentional coughs, submitted via a uniquely devised mobile application. Tests can be delivered on-demand electronically, are independent of supply chains, and are not limited by shelf-life expiration. The SaMD is scalable – able to process 20,000 tests per second – an ideal solution for large organizations, colleges and universities, and government agencies.

AiThority: The 3 Building Blocks to Make AI Accessible

[To share your insights with us, please write to sghosh@martechseries.com]

The post RAIsonance, Inc. Announces BARDA Contract to Continue Development of the AudibleHealth Dx Diagnostic SaMD for COVID-19 and Influenza Through AI-Powered Cough Analysis appeared first on AiThority.

diagnostic
biomedical
health
medical
device
artificial intelligence
ai
data analytics
software
research
department of health